Fellowship Details & Requirements

Our Graduate Medical Education (GME) Office has preliminary eligibility requirements that all prospective trainees must meet before applying for a training program at our institution. In addition to these criteria, our program also the following requirements:

Eligible applicants will have completed a four-year residency program in obstetrics and gynecology accredited by the Accreditation Council for Graduate Medical Education (ACGME) in the U.S., or a five-year residency program in Canada accredited by the Royal College of Physicians and Surgeons of Canada, and are eligible to take the American Board of Obstetrics and Gynecology written examination. Applicants must be U.S. citizens or have U.S. permanent residency status at the time of application.

Each applicant is reviewed by an Admissions Committee comprised of faculty and fellows. Top applicants, chosen based on their credentials and letters of recommendation, are invited for a formal interview. For the 2024 interview season, we will be conducting in-person interviews.

The deadline for submission of applications for the 2025 Gynecologic Oncology Fellowship is April 1, 2025, for a position beginning July 1, 2026. Interviews will take place in August in person.

Interviews take place over a half day and include the participation of the staff. Applicants have the opportunity to meet with faculty and current fellows. The final selection of fellows is made in a series of joint meetings of all staff members. All fellows are selected through the National Residency Matching Program. The salary and fringe benefits are competitive. 

Required documents

In addition to the ERAS application, your completed application package must include:

• Three letters of recommendation (one from a program director) addressed to "Dear Program Director"
• We will accept (but do not require) the SGO standard letter of recommendation
• Personal statement
• Official transcript from each medical school attended
• USMLE transcript including all attempts
• Recent photograph
• CREOG scores - please email to mgduhon@mdanderson.org

Additional documents for foreign medical school applicants

Note: Documents in a language other than English must be submitted with a certified translation.

• Transcript of all college education
• ECFMG certificate

Additional documentation may be required before a candidate can be appointed.

Sample contract for prospective trainees

A sample contract for prospective trainees may be viewed here.

Our gynecologic oncology fellowship aims to train the next generation of academic gynecologic oncologists who will:  provide excellent surgical and medical care to women with gynecologic malignancies, advance the field of gynecologic oncology in translational research, clinical research, and education, and become leaders in the field of gynecologic oncology at the local, national and international level.

The fellowship aligns its goals and objectives with the Accreditation Council for Graduate Medical Education's (ACGME) six core competencies to ensure comprehensive training and development of fellows in the field of gynecologic oncology.

Patient Care

Our program emphasizes providing fellows with comprehensive training in state-of-the-art clinical care for patients with gynecologic cancers. Fellows will gain hands-on experience in the operating room, inpatient and outpatient settings, participating in the diagnosis, surgical management, medical treatment, and long-term follow-up care of patients.

Medical Knowledge

Through structured educational activities, including lectures, journal clubs, and case conferences, fellows will acquire a thorough understanding of the pathophysiology, diagnosis, and management of gynecologic cancers in patients. Fellows will also engage in research endeavors to deepen their medical knowledge and contribute to advancing the field.

Practice-Based Learning and Improvement

Fellows will develop critical thinking and problem-solving skills through active participation in patient care, research projects, and scholarly activities. They will receive mentorship from experienced faculty members to continually assess and enhance their clinical practice and research endeavors.

Interpersonal and Communication Skills

Fellows will refine their communication skills to effectively interact with patients, families, and interdisciplinary healthcare teams. They will learn to convey complex medical information in a clear and empathetic manner, fostering meaningful relationships with patients and facilitating collaborative care.

Professionalism

Our program instills values of professionalism, integrity, and ethical conduct in fellows, preparing them to uphold the highest standards of patient care, research integrity, and professional responsibility. Fellows will learn to navigate challenging ethical dilemmas and demonstrate respect, compassion, and cultural sensitivity in their interactions with patients and colleagues.

Systems-Based Practice

Fellows will gain insight into the healthcare system's structure and function, learning to navigate complex healthcare environments and advocate for optimal patient outcomes. They will collaborate with interdisciplinary teams to improve patient care quality, safety, and efficiency, while also understanding the socioeconomic and cultural factors influencing healthcare delivery.

By integrating these core competencies into our fellowship program, we aim to produce highly skilled and compassionate gynecologic oncology specialists who are equipped to excel in clinical practice, research, and leadership roles within academic medicine. Our fellows will emerge from the program with the knowledge, skills, and professionalism necessary to make meaningful contributions to the field of gynecologic oncology and provide exceptional care to patients and their families.

The Gynecologic Oncology Fellowship Program at MD Anderson is Accreditation Council for Graduate Medical Education (ACGME) accredited (#2254822001). There are three new fellow positions per year, with a total of 12 fellows in the program at any one time. Our program was continuously accredited by the American Board of Obstetrics and Gynecology (ABOG) since the inception of subspecialty certification in 1973, until 2017 when ABOG discontinued accreditation of all gynecologic oncology programs and they were transitioned to ACGME accreditation.

The curriculum includes 24 months of research followed by 24 months of clinical training in gynecologic oncology. The research period permits fellows to pursue interests in either laboratory or clinical research with no routine patient responsibilities. 

Research opportunities and training

The first two years of our four-year fellowship are dedicated to research. Our research fellows are funded on a prestigious NIH T32 training grant. We have three general research tracks: translational science, health services research, and clinical trialist. Soon after matching in our program, incoming fellows will meet with program leadership to discuss their research goals and interests to help place them in the appropriate track and identify mentors. Additionally, our fellows have the opportunity to work with, learn from, and collaborate with faculty members in our department as well as with research mentors across the institution. This includes Radiation Oncology, Surgical Oncology, and Investigational Cancer Therapeutics faculty members to name just a few. During the research years, our fellows will have both a primary T32 mentor as well as secondary mentors to help them realize their research goals. Currently, fellows who do not already have an additional master’s level degree (or higher) will enroll and either earn an M.P.H. or M.S. degree from The University of Texas Health Science Center at Houston. During these two years, fellows are encouraged to submit and present their research at national meetings such as SGO, AACR, and ASCO.

Clinical training

At MD Anderson, our fellows are responsible for supervising and teaching our rotating residents.  Each month, we have residents rotating from the University of Texas Medical Branch (UTMB) and as Felix Rutledge Fellows from residency programs throughout the country. Our fellows help orient these residents to clinical practice at MD Anderson, supervise their management of inpatients on the floor, and help teach them in the operating room. They also run informal teaching sessions with the residents.

During rotations at LBJ hospitals, the clinical fellows lead a team that includes a third year resident, third year medical student, and (during some blocks) a rotating fourth year medical student. Fellows are responsible for supervising and teaching the residents and fellows on the wards, in the outpatient clinic and in the OR. There is a focus on educating the fellows as teachers during this rotation.

Didactics

There is dedicated, protected, didactic time weekly on Monday afternoons. Lectures on various topics in gynecologic oncology are given by faculty members in the Department of Gynecologic Oncology and Reproductive Medicine as well as from our Radiation Oncology, Medical Oncology, and Pathology departments. We also have lectures from our clinical pharmacists, nutritionists, and from our Critical Care faculty. There is also a weekly pre-op conference where OR cases for the upcoming week are reviewed and discussed.

Career Development

Fellows are afforded the opportunity and encouraged to participate and present in regional and national conferences as well as serve on national committees such as the Society of Gynecologic Oncology, NRG Oncology and ASCO.

Scheduling Expectations

Our program adheres to the ACGME requirements for trainee working hours and takes these requirements seriously. 

During on call hours, we have a nocturnalist who helps manage inpatients on the floor, while the on-call fellow is responsible for seeing Emergency Room consults and admissions. Fellows are not required to remain “in house,” but we do have an on-call room available for them to sleep when on call. Because fellows may take call from home, they are required to live within 20 minutes from the hospital.

Board certification

Upon satisfactory completion of the four-year fellowship program, each fellow is eligible to take the written and oral examinations of the American Board of Obstetrics and Gynecology for Board Certification in Gynecologic Oncology.

In the past year, our fellows have won the following awards.

2024 Awards

2023 Awards

Jeffrey How, M.D., MPH, MS, Assistant Professor, Gynecologic Oncology and Reproductive Medicine, 2023 Alumnus

Lymphatic Mapping and Sentinel Node Biopsy in High-Grade Uterine Cancers

Publication: Current Oncology
Authors: How JA, Frumovitz M, Stewart KI, Soliman PT

Clinical Outcomes of Authors: Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

Publication: Cancers (Basel)
Authors: How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A

How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA.

Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer

Publication: Gynecologic Oncology 
Authors: How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Publication: Invest New Drugs 
Authors: How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A

Post-operative gastroparesis following carbohydrate loading in a diabetic patient

Publication: Gynecologic Oncology 
Authors: How JA, Siedel JH, Shafer A. 

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Publication: Scientific Reports
Authors: How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A

Immuno-Oncology for Gynecologic Malignancies

Publication: Advances in Experimental Medicine and Biology
Authors: How JA, Patel A, Jazaeri AA

Roni Nitecki Wilke, M.D., MPH, Assistant Professor, Gynecologic Oncology and Reproductive Medicine, 2023 Alumna

MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial?

Publication: International Journal of Gynecological Cancer
Authors: Nitecki R, Ramirez PT, Dundr P, Nemejcova K, Ribeiro R, Vieira Gomes MT, Schmidt RL, Bedoya L, Isla DO, Pareja R, Rendón Pereira GJ, Lopez A, Kushner D, Cibula D

Growing teratoma syndrome

Publication: International Journal of Gynecological Cancer
Authors: Nitecki R, Hameed N, Bhosale P, Shafer A

Innovation in Cancer Surgery: Maintaining Focus on Survival as the Critical Outcome

Publication: Journal of Minimally Invasive Gynecology 
Authors: Nitecki R, Boruta D

Employment disruption among women with gynecologic cancers

Publication: International Journal of Gynecological Cancer
Authors: Nitecki R, Fu S, Jorgensen KA, Gray L, Lefkowits C, Smith BD, Meyer LA, Melamed A, Giordano SH, Ramirez PT, Rauh-Hain JA

Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Ovarian Cancer

Publication: Obstetrics & Gynecology
Authors: Nitecki R, Clapp MA, Fu S, Lamiman K, Melamed A, Brady PC, Kaimal A, Del Carmen MG, Woodard TL, Meyer LA, Giordano SH, Ramirez PT, Rauh-Hain JA

Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer

Publication: Gynecologic Oncology 
Authors: Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials

Publication: Gynecologic Oncology 
Authors: Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA

Facilitated cascade testing (FaCT): a randomized controlled trial

Publication: International Journal of Gynecological Cancer
Authors: Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK

Employment disruption following the diagnosis of endometrial cancer

Publication: Gynecologic Oncology 
Authors: Nitecki R, Fu S, Lefkowits C, Smith BD, Meyer LA, Melamed A, Giordano SH, Rauh-Hain JA

Fertility-Sparing Treatment for Early-Stage Cervical, Ovarian, and Endometrial Malignancies

Publication: Obstetrics & Gynecology
Authors: Nitecki R, Woodard T, Rauh-Hain JA

Travis T. Sims, M.D., MPH, Assistant Professor, Gynecologic Oncology and Reproductive Medicine, 2022 Alumnus

Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation

Publication: International Journal of Gynecological Cancer
Authors: Sims TT, Jazaeri AA

Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?

Publication: Gynecologic Oncology 
Authors: Sims TT, Boruta DM

Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation

Publication: Communications Biology
Authors: Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH

Intensified Systemic Therapy Regimens in Combination With Definitive Radiation for Treatment of Cervical Cancer

Publication: International Journal of Gynecological Cancer
Authors: Sims TT, Biegert GWG, Ramogola-Masire D, Ngoni K, Solley T, Ning MS, El Alam MB, Mezzari M, Petrosino J, Zetola NM, Schmeler KM, Colbert LE, Klopp AH, Grover S

Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls

Publication: Gynecologic Oncology 
Authors: Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR, Klopp A

R. Tyler Hillman, M.D., Ph.D., Assistant Professor, Gynecologic Oncology and Reproductive Medicine, 2020 Alumnus

Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors

Publication: Gynecologic Oncology
Authors: Hillman RT, Lin DI, Lawson B, Gershenson DM

Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery

Publication: International Journal of Gynecological Cancer
Authors: Hillman RT, Iniesta MD, Shi Q, Suki T, Chen T, Cain K, Williams L, Wang XS, Taylor JS, Mena G, Lasala J, Ramirez PT, Meyer LA

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

Publication: PLOS One
Authors: Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M

Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program

Publication: Gynecologic Oncology
Authors: Hillman RT, Sanchez-Migallon A, Meyer LA, Iniesta MD, Cain KE, Siverand AM, Veum SPL, Suki TS, Lasala JD, Ramirez PT

KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary

Publication: Nature Communications
Authors: Hillman RT, Celestino J, Terranova C, Beird HC, Gumbs C, Little L, Nguyen T, Thornton R, Tippen S, Zhang J, Lu KH, Gershenson DM, Rai K, Broaddus RR, Futreal PA

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer

Publication: Journal of the National Cancer Institute
Authors: Hillman RT, Chisholm GB, Lu KH, Futreal PA

Samantha Batman, M.D., MPH, Current Fellow

A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study

Publication: Cancer Epidemiology, Biomarkers & Prevention
Authors: Batman S, Messick CA, Milbourne A, Guo M, Munsell MF, Fokom-Domgue J, Salcedo M, Deshmukh A, Dahlstrom KR, Ogburn M, Price A, Fleming ND, Taylor J, Shafer A, Cobb L, Sigel K, Sturgis EM, Chiao EY, Schmeler KM

Fertility-Sparing and Less Radical Surgery for Cervical Cancer

Publication: Current Oncology Reports
Authors: Batman SH, Schmeler KM

Kirsten Jorgensen, M.D., MPH, Current Fellow

All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer

Publication: Gynecologic Oncology
Authors: Jorgensen K, Denham C, Kanbergs A, Wu CF, Nitecki R, Agusti N, Meernik C, Melamed A, Rauh-Hain JA

Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy

Publication: Gynecologic Oncology
Authors:  Jorgensen K, Melamed A, Wu CF, Nitecki R, Pareja R, Fagotti A, Schorge JO, Ramirez PT, Rauh-Hain JA

Disparities in Fertility-Sparing Treatment and Use of Assisted Reproductive Technology After a Diagnosis of Cervical, Ovarian, or Endometrial Cancer

Publication: Obstetrics and Gynecology
Authors:  Jorgensen K, Meernik C, Wu CF, Murphy CC, Baker VL, Jarmon P, Brady PC, Nitecki R, Nichols HB, Rauh-Hain JA

Obstetric and Neonatal Outcomes 1 or More Years After a Diagnosis of Breast Cancer

Publication: Obstetrics and Gynecology
Authors:  Jorgensen K, Nitecki R, Nichols HB, Fu S, Wu CF, Melamed A, Brady P, Chavez Mac Gregor M, Clapp MA, Giordano S, Rauh-Hain JA

Fertility-sparing surgery vs standard surgery for early-stage cervical cancer: difference in 5-year life expectancy by tumor size

Publication: American Journal of Obstetrics and Gynecology
Authors:  Jorgensen KA, Agusti N, Wu CF, Kanbergs A, Pareja R, Ramirez PT, Rauh-Hain JA, Melamed A

Ji Youn “Jessica" Son, MD, MS

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Publication: Journal of Immunotherapy and Precision Oncology
Authors: Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis

Publication: Gynecologic Oncology
Authors: Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, Hong DS

Amma Asare, M.D., Ph.D., Current Fellow

Race-associated molecular changes in gynecologic malignancies

Publication: Cancer Research Communications
Authors: Asare A, Yao H, Lara OD, Wang Y, Zhang L, Sood AK

Anne Knisely, M.D., Current Fellow

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

Publication: iScience
Authors: Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA

Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center

Publication: American Journal of Obstetrics and Gynecology
Authors: Knisely A, Iniesta MD, Marten CA, Chisholm G, Schmeler KM, Taylor JS

Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis

Publication: Med
Authors: Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA

Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center

Publication: Gynecologic Oncology
Authors: Knisely A, Iniesta MD, Batman S, Meyer LA, Soliman PT, Cain KE, Marten C, Chisholm G, Schmeler KM, Taylor JS, Fleming ND

Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Publication: Cancer
Authors: Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A

Alexa Kanbergs, M.D., MS, M.Sc., Current Fellow

Patient Location and Disparities in Access to Fertility Preservation for Women With Gynecologic or Breast Cancer

Publication: Obstetrics and Gynecology
Authors: Kanbergs A, Jorgensen K, Agusti N, Viveros-Carreño D, Wu CF, Nitecki R, Harris JA, Woodard T, Ramphul R, Rauh-Hain JA

Our faculty members are international experts with decades of expertise in Gynecologic Oncology. The Gynecologic Oncology and Reproductive Medicine department provides world-class comprehensive care of women with gynecologic cancers. As international leaders in the field, our physicians are driving innovations in cancer care through clinical trials, translational research, advanced surgical techniques and cancer prevention efforts. Our faculty members treat patients with all types of gynecologic cancers, including ovarian cancer, endometrial (uterine) cancer, cervical cancer, vulvar cancer, vaginal cancer, gestational trophoblastic disease, and others. In addition, we have specialty clinics focusing on cervix pre-invasive disease, high-risk ovarian cancer screening, oncofertility and acute gynecology issues in cancer patients.
 

In addition to gaining unparalleled education and training experience, MD Anderson trainees have access to exceptional resources and benefits to help them build meaningful careers and lead fulfilling lives.

Institutional benefits and support

GME trainees’ salary stipends are updated every year based on the ACGME’s recommendations, and because our trainees are considered workforce members, they also enjoy MD Anderson’s employee benefits, including health insurance, retirement planning, disability insurance and six weeks of parental leave.

Our GME House Staff Senate offers trainees the opportunity to experience a leadership role in a medical field career, and the institution’s Academic Mentoring Council provides avenues to secure tailored academic mentoring from faculty. Our GME trainees benefit from the extensive support offered to our research trainees, too; they are invited to participate in grant application workshops, apply for pilot grants to support their research ideas and receive monetary awards for securing extramural grant funding.

Trainee wellness is also of utmost importance at MD Anderson.

Our trainees have access to MD Anderson’s employee networks, fitness center and other wellness resources provided by the institution. Additionally, our Graduate Medical Education Committee (GMEC), which provides oversight of our accredited programs, regularly assess our trainees’ needs and implements various initiatives, such as providing free call meals and discounted parking to GME House Staff, to address those gaps. The committee even has a subcommittee entirely dedicated to supporting the wellness of our trainees.

Our efforts to ensure a welcoming and supportive education and training experience have been commended nationally. In 2023, the Office of Graduate Medical Education received the DeWitt C. Baldwin, Jr. Award, a prestigious national award that recognizes our institution for its respectful and supportive environment for delivering medical education and patient care.

Beyond MD Anderson

MD Anderson’s location has many benefits, too. Our main campus is nestled inside the Texas Medical Center, the world’s largest medical center which boasts about 10 million patient encounters each year. Many of our faculty are involved in interorganizational research collaborations, both within the TMC and across the nation, exposing trainees to groundbreaking advancements in medical care in real time.

Most importantly, the city of Houston is a great place to call home and raise a family. We are one of the most culturally diverse cities in the nation. More than 145 different languages are spoken across the city, placing us behind only New York and Los Angeles. In fact, about 30% of the city’s population speaks a language other than English at home. And, paychecks here stretch farther than most U.S. metro areas, thanks to our low cost of living.

Visit our Why Houston page to learn more about our city’s affordable housing, fine dining, entertainment scene, nationally renowned museums and other great attributes.